Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

Blood (2021) 138 (Supplement 1): 3753.

https://doi.org/10.1182/blood-2021-150961

Published: 2021

Journal Articles

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma

Jeremy S. Abramson, Jon E. Arnason, Ann S. LaCasce, Robert Redd, Jeffrey A. Barnes, Lubomir Sokol, Robin Joyce, David Avigan, Donna Neuberg, Ronald W. Takvorian, Ephraim P. Hochberg, Celeste M. Bello

Blood (2019) 134 (7): 606–613.

https://doi.org/10.1182/blood.2019001272

Published: 2019

Includes: Supplemental data

Journal Articles

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells

Philipp Karschnia, Justin T. Jordan, Deborah A. Forst, Isabel C. Arrillaga-Romany, Tracy T. Batchelor, Joachim M. Baehring, Nathan F. Clement, L. Nicolas Gonzalez Castro, Aline Herlopian, Marcela V. Maus, Michaela H. Schwaiblmair, Jacob D. Soumerai, Ronald W. Takvorian, Ephraim P. Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Matthew J. Frigault, Jorg Dietrich

Blood (2019) 133 (20): 2212–2221.

https://doi.org/10.1182/blood-2018-12-893396

Published: 2019

Journal Articles

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Matthew S. Davids, MD, Haesook T Kim, PhD, Danielle M. Brander, MD, Jad Bsat, BA, Alexandra Savell, BS, Karen Francoeur, RN, Caron Jacobson, MD, Samuel Y. Ng, MDPhD, Ann S LaCasce, MD MSc, Ephraim P. Hochberg, MD, Ronald W. Takvorian, MD, Jeremy S. Abramson, MD MMSc, David C. Fisher, MD PhD, Jennifer R. Brown, MD PhD

Blood (2017) 130 (Supplement 1): 496.

https://doi.org/10.1182/blood.V130.Suppl_1.496.496

Published: 2017

Journal Articles

Notch-Regulated Enhancers in B-Cell Lymphoma Activate MYC and Potentiate B-Cell Receptor Signaling

Russell J.H. Ryan, MD, Jelena Petrovic, PhD, Dylan Rausch, BS, Caleb Lareau, BS, Winston Lee, MD PhD, Laura Donohue, BS, Amanda L. Christie, BS, Shawn Gillespie, BS, Michael J. Kluk, MD PhD, Valentina Nardi, MD, Robert B. Faryabi, PhD, Ephraim P. Hochberg, MD, David M. Weinstock, MD, Bradley E. Bernstein, MD PhD, Jon C. Aster, MD PhD, Warren S. Pear, MD PhD

Blood (2016) 128 (22): 457.

https://doi.org/10.1182/blood.V128.22.457.457

Published: 2016

Journal Articles

Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations

Blood (2016) 128 (8): 1093–1100.

https://doi.org/10.1182/blood-2015-12-682591

Published: 2016

Includes: Supplemental data

Journal Articles

Pediatric-Type Nodal Follicular Lymphoma in Children and Adults Is Nearly Genetically Silent and Biologically Distinct from Typical Follicular Lymphoma

Abner Louissaint, Jr., MD PhD, Kristian T. Schafernak, MD MPH, Julia T. Geyer, MD, Alexandra E. Kovach, MD, Dita Gratzinger, MD PhD, Christine G. Roth, MD, Christian N. Paxton, PhD, Sunhee Kim, Chungdak Namgyal, Elizabeth A. Morgan, MD, Sarah T. South, PhD, Marian H. Harris, MD PhD, Ephraim P. Hochberg, MD, Robert P. Hasserjian, MD, Nancy L. Harris, MD, David M. Weinstock, MD

Blood (2015) 126 (23): 3925.

https://doi.org/10.1182/blood.V126.23.3925.3925

Published: 2015

Journal Articles

Panobinostat in Combination with Rituximab in Heavily Pretreated Diffuse Large B-Cell Lymphoma: Results of a Phase II Study

Jeffrey A. Barnes, MD PhD, Robert Allyn Redd, MS, Eric D. Jacobsen, MD, David C. Fisher, MD, Arnold S. Freedman, MD, Ephraim P Hochberg, MD, Tak Takvorian, MD, Donna Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2014) 124 (21): 3055.

https://doi.org/10.1182/blood.V124.21.3055.3055

Published: 2014

Journal Articles

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas: Final Results from a Phase 1-2 Trial

Jeremy S. Abramson, MD, Eric D. Jacobsen, MD, Robert Allyn Redd, MS, Tak Takvorian, MD, David C. Fisher, MD, Jennifer R. Brown, Joel H Schwartz, MD, James Weitzman, MD, Donna Neuberg, ScD, Jeffrey A. Barnes, MD PhD, Ephraim P Hochberg, MD

Blood (2014) 124 (21): 4423.

https://doi.org/10.1182/blood.V124.21.4423.4423

Published: 2014

Journal Articles

Inhibition of Phosphorylation of ERK in CLL Cells Pre-Treatment Correlates Best with Response to Dasatinib, Fludarabine, and Rituximab for Patients with Relapsed CLL

Philip C. Amrein, MD, Xin Kai, Yasuyuki Iuchi, Jon Arnason, MD, Jennifer R. Brown, MD PhD, Karen K. Ballen, MD, Eyal C. Attar, MD, Amir T Fathi, Ephraim P. Hochberg, HyukJoo Hwang, Shiv Pillai

Blood (2014) 124 (21): 3636.

https://doi.org/10.1182/blood.V124.21.3636.3636

Published: 2014

Journal Articles

Inhibition Of Lyn and Syk By Treatment With Dasatinib, Fludarabine, and Rituximab Correlates With Apoptosis and Clinical Response In Patients With Relapsed CLL

Philip C. Amrein, MD, Xin Kai, Carlos Donato, Jon Arnason, MD, Jennifer R. Brown, M.D., Karen K. Ballen, MD, Eyal C. Attar, MD, Amir T. Fathi, MD, Ephraim P Hochberg, MD, HyukJoo Hwang, Lillian Werner, Donna Neuberg, ScD, Shiv Pillai, MD, PhD

Blood (2013) 122 (21): 5300.

https://doi.org/10.1182/blood.V122.21.5300.5300

Published: 2013

Journal Articles

Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance

Blood (2013) 122 (21): 741.

https://doi.org/10.1182/blood.V122.21.741.741

Published: 2013

Journal Articles

Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial

Jeffrey A. Barnes, MD, PhD, Yang Feng, PhD, Ephraim P Hochberg, MD, Tak Takvorian, MD, James Weitzman, MD, David C. Fisher, MD, Eric D. Jacobsen, MD, Robin Joyce, MD, Donna S. Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2013) 122 (21): 3062.

https://doi.org/10.1182/blood.V122.21.3062.3062

Published: 2013

Journal Articles

Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy

Jeremy S. Abramson, MD, Jeffrey A. Barnes, MD, PhD, Yang Feng, PhD, Tak Takvorian, MD, Donna S. Neuberg, ScD, Ephraim P. Hochberg, MD, Aliyah R. Sohani, MD

Blood (2012) 120 (21): 1619.

https://doi.org/10.1182/blood.V120.21.1619.1619

Published: 2012

Journal Articles

Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement

Abner Louissaint, Jr, Adam M. Ackerman, Dora Dias-Santagata, Judith A. Ferry, Ephraim P. Hochberg, Mary S. Huang, A. John Iafrate, Daniel O. Lara, Geraldine S. Pinkus, Itziar Salaverria, Zakir Siddiquee, Reiner Siebert, Howard J. Weinstein, Lawrence R. Zukerberg, Nancy Lee Harris, Robert P. Hasserjian

Blood (2012) 120 (12): 2395–2404.

https://doi.org/10.1182/blood-2012-05-429514

Published: 2012

Includes: Supplemental data

Journal Articles

The Clinical Course of Head and Neck Cancer in Patients with Chronic Lymphocytic Leukemia

Aaron D Maybury, Ephraim P. Hochberg, MD, Lori J Wirth, MD, Jeremy S. Abramson, MD, Kevin S Emerick, MD, James S. Michaelson, PhD, Christiana E. Toomey, Kristina Cibor, Brad Diephuis, Devon Bush

Blood (2011) 118 (21): 4741.

https://doi.org/10.1182/blood.V118.21.4741.4741

Published: 2011

Journal Articles

Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,

Jeffrey A. Barnes, MD, PhD, Kristen Stevenson, Ephraim P. Hochberg, MD, Tak Takvorian, MD, David C. Fisher, MD, Ann LaCasce, MD, Jennifer R. Brown, MD, PhD, Anuj K. Mahindra, MD, Donna Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2011) 118 (21): 3716.

https://doi.org/10.1182/blood.V118.21.3716.3716

Published: 2011

Journal Articles

Secondary Central Nervous System Lymphoma: A Single Center Experience

Gregory M. Cote, MD, PhD, Yang Feng, PhD, Aliyah R. Sohani, MD, Zachary J. Roberts, MD, PhD, Anna Colpo, MD, Fred H Hochberg, MD, Yi-Bin A. Chen, MD, James S. Michaelson, PhD, Donna Neuberg, ScD, Jeremy S. Abramson, MD, Ephraim P. Hochberg, MD

Blood (2011) 118 (21): 5181.

https://doi.org/10.1182/blood.V118.21.5181.5181

Published: 2011

Journal Articles

Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma

Jeffrey A. Barnes, MD, PhD, Eric Jacobsen, MD, Yang Feng, PhD, Arnold S. Freedman, MD, Ephraim P. Hochberg, MD, Ann S. LaCasce, MD, Philippe Armand, MD, PhD, Robin Joyce, MD, Donna Neuberg, ScD, David C. Fisher, MD, Jeremy S. Abramson, MD

Blood (2011) 118 (21): 1635.

https://doi.org/10.1182/blood.V118.21.1635.1635

Published: 2011

Journal Articles

B Cell Lymphoma In Association with Multiple Myeloma: Analysis of the Biologic Relationship

Anuj K. Mahindra, MD, Aliyah R. Sohani, MD, Christiana E. Toomey, James S. Michaelson, PhD, Jeffrey A. Barnes, MD, PhD, Jeremy S. Abramson, MD, Ronald Takvorian, MD, Noopur S. Raje, MD, Ephraim P. Hochberg, MD

Blood (2011) 118 (21): 1590.

https://doi.org/10.1182/blood.V118.21.1590.1590

Published: 2011

NARROW

Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Notch-Regulated Enhancers in B-Cell Lymphoma Activate MYC and Potentiate B-Cell Receptor Signaling

Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations

Pediatric-Type Nodal Follicular Lymphoma in Children and Adults Is Nearly Genetically Silent and Biologically Distinct from Typical Follicular Lymphoma

Panobinostat in Combination with Rituximab in Heavily Pretreated Diffuse Large B-Cell Lymphoma: Results of a Phase II Study

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas: Final Results from a Phase 1-2 Trial

Inhibition of Phosphorylation of ERK in CLL Cells Pre-Treatment Correlates Best with Response to Dasatinib, Fludarabine, and Rituximab for Patients with Relapsed CLL

Inhibition Of Lyn and Syk By Treatment With Dasatinib, Fludarabine, and Rituximab Correlates With Apoptosis and Clinical Response In Patients With Relapsed CLL

Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance

Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial

Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy

Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement

The Clinical Course of Head and Neck Cancer in Patients with Chronic Lymphocytic Leukemia

Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,

Secondary Central Nervous System Lymphoma: A Single Center Experience

Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma

B Cell Lymphoma In Association with Multiple Myeloma: Analysis of the Biologic Relationship

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only